O. Brehar

Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

R. Houot, C. Copie-Bergman, B. Coiffier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

E. Clappier, S. Chevret, P. Fenaux, 2021, Blood.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, European journal of haematology.

Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

B. Coiffier, P. Feugier, S. Leprêtre, 2011 .

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, European journal of haematology.